Methods for enhancing the release and absorption of water insoluble active agents
View Patent ↗Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.
1. Microparticles comprising at least one water-insoluble active agent obtained by
(a) dissolving, melting, or suspending at least one water-insoluble active agent in at least one fatty acid, conjugated fatty acid, or combinations thereof to form a mixture, and
(b) mixing the mixture of step (a) with a liquid hydrophilic or lipophilic carrier to form the microparticles having a diameter from 100 nm to 25 microns, and
wherein the microparticles and carrier are encapsulated in a soft or hard, gelatin, or non-gelatin capsule.
2. The particles of claim 1 , wherein step (a) further comprises at least one surfactant, hydrophilic polymer, or combinations thereof.
3. The particles of claim 2 , wherein the concentration of the surfactant is from about 1% to about 50% by weight of the microparticles.
4. The particle of claim 2 , wherein the concentration of the hydrophilic polymer is from about 1% to about 50% by weight of the microparticles, or if the hydrophilic polymer is polyethylene glycol, the concentration is from about 1% to about 80% by weight of the microparticles.
5. The microparticles of claim 1 , wherein the active agent has an enhanced rate of dissolution in aqueous media compared to a formulation containing the active agent suspended in aqueous media under fed or fasting conditions.
6. The particles of claim 2 , wherein the surfactant in step (a) has an HLB greater than about 10.
7. The particles of claim 6 , wherein the surfactant in step (a) has an HLB greater than about 16.
8. The particles of claim 1 , wherein the conjugated fatty acid is selected from the group consisting of C 10 -C 18 monoglycerides, C 10 -C 18 fatty acids conjugated to a polyalkylene oxide, C 10 -C 18 fatty acids conjugated to a monosaccharide, and combinations thereof.
9. The particles of claim 1 , wherein the fatty acid is a C 10 -C 18 fatty acid.
10. The particles of claim 9 , wherein the fatty acid is selected from the group consisting of dodecanoic (lauric) acid, tetradecanoic (myristic) acid, hexadecanoie (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, eicosanoic (arachidic) acid, docosanoic (behenic) acid, tetracosanoic (lignoceric) acid, hexacosanoic (cerotic) acid, heptacosanoic (carboceric) acid, octacosanoic (montanic) acid, triacontanoic (melissic) acid, dotriacontanoic (lacceroic) acid, tritriacontanoic (ceromelissic) acid, tetratriacontanoic (geddic) acid, pentatriacontanoic (ceroplastic) acid, and combinations thereof.
11. The particles of claim 2 , wherein the hydrophilic polymer is selected from the group consisting of poloxomers, poloxamines, and polyethylene glycols.
12. The particles of claim 1 , wherein the water-insoluble active agent is selected from the group consisting of fenofibrate, cilostazol, acetazolamide, albendazole, allopurinol, azothioprine, carbamazepine, clofazimine, dapsone, diazepam, diloxanide furoate, doxycycline, efavirenz, furosemide, glibenclamide, griseofulvin, haloperidol, ibuprofen, lopinavir, nevirapine, niclosamide, nifedipine, paracetamol, parathyroid calcitonin, retinol palmitate, ritonavir, sulfadiazine, sulfamethoxazole, and sulfasalazine.
13. The particles of claim 1 , wherein the active agent is fenofibrate or cilostazol.
14. The particles of claim 1 , wherein the concentration of the fatty acid or conjugated fatty acid is from about 5% to about 15% by weight of the particles plus carrier.
15. The particles of claim 2 , wherein the concentration of the surfactant is from about 5% to about 15% by weight of the particles plus carrier.
16. The particles of claim 2 , wherein the concentration of the hydrophilic polymer is from about 5% to about 15% by weight of the microparticles and carrier.
17. The particles of claim 11 , wherein the concentration of polyethylene glycol is from about 30% to about 60% by weight of the microparticles and carrier.
18. The particles of claim 11 , wherein the concentration of polyethylene glycol is from about 40% to about 60% by weight of the microparticles and carrier.
19. The particles of claim 1 , wherein the hydrophilic or lipophilic carrier in step (b) is at or below room temperature.
20. The particles of claim 1 , wherein the particles have a diameter between 5 microns and 25 microns.
21. The particles of claim 6 , wherein the surfactant in step (a) has an HLB value greater than about 14.
22. The particles of claim 2 , comprising a surfactant and at least one fatty acid or conjugated fatty acid, hydrophilic polymer, or combinations thereof.
23. The particles of claim 1 , wherein when the active agent is fenofibrate, the percent dissolution of fenofibrate is about 85% after 30 minutes when conducted using a USP dissolution apparatus II (paddles) at 75 rpm in 1000 ml of 0.05 M sodium dodecyl sulfate at 37°±0.5° C.
24. The particles of claim 23 , wherein when the active agent is fenofibrate, the percent dissolution of fenofibrate is about 95% after 45 minutes.
25. The particles of claim 23 , wherein when the active agent is fenofibrate, the percent dissolution of fenofibrate is about 100% after 60 minutes.